Improving colorectal cancer screening programs  

作　　者：Oscar J Cordero Lucia Mosquera-Ferreiro Iria Gomez-Tourino 

机构地区：[1]Department of Biochemistry and Molecular Biology,University of Santiago de Compostela,Santiago de Compostela 15782,Spain [2]Centre for Research in Molecular Medicine and Chronic Diseases(CiMUS),University of Santiago de Compostela,Santiago de Compostela 15782,Galicia,Spain

出　　处：《World Journal of Gastroenterology》2024年第22期2849-2851,共3页世界胃肠病学杂志（英文版）

基　　金：Xunta de Galicia(Ayudas de Consolidación y Estructuración de Unidades de Investigación Competitivas de la Consellería de Cultura,Educación,Formación Profesional y Universidades,GRC,ED431C 2023/28 and GRC,ED431C 2023/09).

摘　　要：In this editorial we comment on the article by Agatsuma et al published in the World Journal of Gastroenterology.They suggest policies for more effective colorectal screening.Screening is the main policy that has led to lower mortality rates in later years among the population that was eligible for screening.Colonoscopy is the gold standard tool for screening and has preventive effects by removing precancerous or early malignant polyps.However,colonoscopy is an invasive process,and fecal tests such as the current hemoglobin immunodetection were developed,followed by endoscopy,as the general tool for population screening,avoiding logistical and economic problems.Even so,participation and adherence rates are low.Different screening options are being developed with the idea that if people could choose between the ones that best suit them,participation in population-based screening programs would increase.Blood tests,such as a recent one that detects cell-free DNA shed by tumors called circulating tumor DNA,showed a similar accuracy rate to stool tests for cancer,but were less sensitive for advanced precancerous lesions.At the time when the crosstalk between the immune system and cancer was being established as a new hallmark of cancer,novel immune system-related biomarkers and information on patients’immune parameters,such as cell counts of different immune populations,were studied for the early detection of colorectal cancer,since they could be effective in asymptomatic people,appearing earlier in the adenoma-carcinoma development compared to the presence of fecal blood.sCD26,for example,detected 80.37%of advanced adenomas.To reach as many eligible people as possible,starting at an earlier age than current programs,the direction could be to apply tests based on blood,urine or salivary fluid to samples taken during routine visits to the primary health system.

关 键 词：Mortality rates Colorectal cancer Screening BIOMARKER Fecal hemoglobin immunodetection Soluble sCD26 COLONOSCOPY Immunoscores 

分 类 号：R735.34[医药卫生—肿瘤]